• 1
    Sakane T, Takeno M, Suzuki N, Inaba G. Behçet's disease. N Engl J Med 1999; 341: 128491.
  • 2
    Yazici H, Yurdakul S, Hamuryudan V. Behçet disease. Curr Opin Rheumatol 2001; 13: 1822.
  • 3
    Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M. Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 2004; 138: 37380.
  • 4
    Kural-Seyahi E, Fresko I, Seyahi N, Ozyazgan Y, Mat C, Hamuryudan V, et al. The long-term mortality and morbidity of Behçet syndrome: a 2-decade outcome survey of 387 patients followed at a dedicated center. Medicine (Baltimore) 2003; 82: 6076.
  • 5
    Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. EULAR recommendations for the management of Behçet disease. Ann Rheum Dis 2008; 67: 165662.
  • 6
    International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet 1990; 335: 107880.
  • 7
    Jabs DA, Nussenblatt RB, Rosenbaum JT, and the Standardization of Uveitis Nomenclature (SUN) Working Group. Standardization of uveitis nomenclature for reporting clinical data: results of the First International Workshop. Am J Ophthalmol 2005; 140: 50916.
  • 8
    Walsh M, Merkel PA, Mahr A, Jayne D. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasm antibody–associated vasculitis: a meta-analysis. Arthritis Care Res (Hoboken) 2010; 62: 116673.
  • 9
    Tugal-Tutkun I, Mudun A, Urgancioglu M, Kamali S, Kasapoglu E, Inanc M, et al. Efficacy of infliximab in the treatment of uveitis that is resistant to treatment with the combination of azathioprine, cyclosporine, and corticosteroids in Behçet's disease: an open-label trial. Arthritis Rheum 2005; 52: 247884.
  • 10
    Gueudry J, Wechsler B, Terrada C, Gendron G, Cassoux N, Fardeau C, et al. Long-term efficacy and safety of low-dose interferon alfa2a therapy in severe uveitis associated with Behçet disease. Am J Ophthalmol 2008; 146: 83744.
  • 11
    Kotter I, Deuter C, Stubiger N, Zierhut M. Interferon-a (IFN-a) application versus tumor necrosis factor-a antagonism for ocular Behçet's disease: focusing more on IFN [letter]. J Rheumatol 2005; 32: 1633.
  • 12
    Cochereau-Massin I, Wechsler B, Le Hoang P, Le Thi Huong D, Girard B, Rousselie F, et al. Ocular prognosis in Behçet's disease. J Fr Ophtalmol 1992; 15: 3437. In French.
  • 13
    Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behçet's syndrome. N Engl J Med 1990; 322: 2815.
  • 14
    Hamuryudan V, Ozyazgan Y, Hizli N, Mat C, Yurdakul S, Tuzun Y, et al. Azathioprine in Behçet's syndrome: effects on long-term prognosis. Arthritis Rheum 1997; 40: 76974.
  • 15
    Pacheco PA, Taylor SR, Cuchacovich MT, Diaz GV. Azathioprine in the management of autoimmune uveitis. Ocul Immunol Inflamm 2008; 16: 1615.
  • 16
    Ahn JK, Chung H, Lee DS, Yu YS, Yu HG. CD8brightCD56+ T cells are cytotoxic effectors in patients with active Behçet's uveitis. J Immunol 2005; 175: 613342.
  • 17
    Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A. Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease. Int Ophthalmol 2005; 26: 8392.
  • 18
    Hamuryudan V, Ozyazgan Y, Fresko Y, Mat C, Yurdakul S, Yazici H. Interferon α combined with azathioprine for the uveitis of Behçet's disease: an open study. Isr Med Assoc J 2002; 4: 92830.
  • 19
    Bodaghi B, Bui Quoc E, Wechsler B, Tran TH, Cassoux N, Le Thi Huong D, et al. Therapeutic use of infliximab in sight threatening uveitis: retrospective analysis of efficacy, safety, and limiting factors. Ann Rheum Dis 2005; 64: 9624.
  • 20
    Wechsler B, Sable-Fourtassou R, Bodaghi B, Huong DL, Cassoux N, Badelon I, et al. Infliximab in refractory uveitis due to Behçet's disease. Clin Exp Rheumatol 2004; 22: S146.
  • 21
    Sfikakis PP, Kaklamanis PH, Elezoglou A, Katsilambros N, Theodossiadis PG, Papaefthimiou S, et al. Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med 2004; 140: 4046.
  • 22
    Wechsler B, Bodaghi B, Huong DL, Fardeau C, Amoura Z, Cassoux N, et al. Efficacy of interferon alfa-2a in severe and refractory uveitis associated with Behçet's disease. Ocul Immunol Inflamm 2000; 8: 293301.
  • 23
    Hatemi G, Silman A, Bang D, Bodaghi B, Chamberlain AM, Gul A, et al. Management of Behçet's disease: a systematic literature review for the EULAR evidence based recommendations for the management of Behçet's disease. Ann Rheum Dis 2008; 67: 165662.